270 related articles for article (PubMed ID: 3681191)
1. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
[TBL] [Abstract][Full Text] [Related]
2. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
3. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.
Szu SC; Bystricky S; Hinojosa-Ahumada M; Egan W; Robbins JB
Infect Immun; 1994 Dec; 62(12):5545-9. PubMed ID: 7960137
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.
Kossaczka Z; Bystricky S; Bryla DA; Shiloach J; Robbins JB; Szu SC
Infect Immun; 1997 Jun; 65(6):2088-93. PubMed ID: 9169736
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
7. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
8. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
9. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
Robbins JD; Robbins JB
J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.
Szu SC; Li XR; Schneerson R; Vickers JH; Bryla D; Robbins JB
Infect Immun; 1989 Dec; 57(12):3823-7. PubMed ID: 2807549
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
[TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
Ali A; An SJ; Cui C; Haque A; Carbis R
Hum Vaccin Immunother; 2012 Feb; 8(2):189-93. PubMed ID: 22426380
[TBL] [Abstract][Full Text] [Related]
13. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
15. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.
Acharya IL; Lowe CU; Thapa R; Gurubacharya VL; Shrestha MB; Cadoz M; Schulz D; Armand J; Bryla DA; Trollfors B
N Engl J Med; 1987 Oct; 317(18):1101-4. PubMed ID: 3657877
[TBL] [Abstract][Full Text] [Related]
16. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
Szu SC; Taylor DN; Trofa AC; Clements JD; Shiloach J; Sadoff JC; Bryla DA; Robbins JB
Infect Immun; 1994 Oct; 62(10):4440-4. PubMed ID: 7927707
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
18. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
19. Development of Vi conjugate - a new generation of typhoid vaccine.
Szu SC
Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
[TBL] [Abstract][Full Text] [Related]
20. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
Tacket CO; Levine MM; Robbins JB
Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]